產(chǎn)品詳情

  • 產(chǎn)品名稱(chēng)：LapatinibDitosylate(Tykerb,Tyverb,GW-572016)

  • 產(chǎn)品型號(hào)：
  • 產(chǎn)品廠商：Biovision
  • 產(chǎn)品文檔：
你添加了1件商品 查看購(gòu)物車(chē)
簡(jiǎn)單介紹：
LapatinibDitosylate(Tykerb,Tyverb,GW-572016)
詳情介紹：
Characteristics Lapatinib is a potent inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM), ErbB-4 kinase (Ki = 347 nM). Lapatinib can restore tamoxifen sensitivity in tamoxifen-resistant, ER-positive breast cancer models.
Purity ≥ 99?% by HPLC
Chemical Name GW-57201, Tykerb, Tyverb
Formula C??H??ClFN?O?S.2C?H?O?S
Permeability Cell-permeable
Molecular Weight 925.46 g/mol
CAS-No 388082-78-8
Restrictions For Research Use only
Format Solid
Handling Advice Protect from air and moisture
Storage -20 °C
Expiry Date 24 months
Supplier Images
image for Lapatinib Ditosylate (Tykerb, Tyverb, GW-572016) (ABIN412229) Lapatinib Ditosylate (Tykerb, Tyverb, GW-572016)
Product cited in: Finigan, Vasu, Thaikoottathil, Mishra, Shatat, Mason, Kern: "HER2 activation results in β-catenin-dependent changes in pulmonary epithelial permeability." in: American journal of physiology. Lung cellular and molecular physiology, Vol. 308, Issue 2, pp. L199-207, 2015 (PubMed).

Minami, Kijima, Otani, Kohmo, Takahashi, Nagatomo, Hirata, Suzuki, Inoue, Takeda, Kida, Tachibana, Kumanogoh: "HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer." in: Molecular cancer therapeutics, Vol. 11, Issue 4, pp. 830-41, 2012 (PubMed).